Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab combined with radiotherapy for unresectable or palliatively resected cholangiocarcinoma
ChiCTR2300078921Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab in cholangiocarcinoma (CCA), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Progression-free survival. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR2300078921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078921.